Skip to main navigation
Skip to search
Skip to main content
the UWA Profiles and Research Repository Home
Login
Link opens in a new tab
Search content at the UWA Profiles and Research Repository
Home
Profiles
Organisations
Research output
Grants
Datasets
Prizes / Awards
Engagement / Activities
Press/Media
Units
Equipment
Impacts
Lupus Erythematodus
Johannes Cornelis Nossent
UWA Medical School
Research output
:
Chapter in Book/Conference paper
›
Entry for encyclopedia/dictionary
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Lupus Erythematodus'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
100%
Antigen Antibody Complex
21%
Prevalence
14%
Screening Test
14%
Skin Defect
14%
B Cell
14%
Immunocompetent Cell
14%
Discoid Lupus Erythematosus
14%
Drug-Induced Lupus Erythematosus
14%
Immune Complex Deposition
14%
Immunosuppressive Drug
14%
Nucleosome
14%
Antinuclear Antibody
14%
Diseases
14%
Antimalarial Agent
7%
Observational Study
7%
Programmed Cell Death
7%
Combination Therapy
7%
Heart Injury
7%
Mediator
7%
Organ Systems
7%
Nonsteroid Antiinflammatory Agent
7%
Pathophysiology
7%
Cyclosporine
7%
Corticosteroid Therapy
7%
Infection
7%
Scar Formation
7%
Connective Tissue Disease
7%
Lupus Nephritis
7%
CD20
7%
Cell Receptor
7%
Thromboembolism
7%
Anti-dsDNA Antibodies
7%
Scalp
7%
Life Expectancy
7%
Skin Manifestation
7%
Drug Efficacy
7%
Disease Course
7%
Alopecia Mucinosa
7%
CD40 Ligand
7%
Maternal Antibody
7%
Ribosome Protein
7%
Biological Therapy
7%
Ro Antibody
7%
Atrioventricular Block
7%
Neonatal Lupus Erythematosus
7%
Hypocomplementemia
7%
Subacute Cutaneous Lupus Erythematosus
7%
Lupus Band Test
7%
Ultraviolet Radiation
7%
Neonatal Infant
7%
Neck
7%
T Cell
7%
Maturation
7%
Drug Delivery System
7%
Atherosclerosis
7%
Osteoporosis
7%
Autoimmune Disease
7%
Monoclonal Antibody
7%
Interleukin 6
7%
Autoantibodies
7%
Autoimmunity
7%
Tacrolimus
7%
Abatacept
7%
Prednisone
7%
Myocardial Disease
7%
Hydralazine
7%
Self-antigens
7%
Lupus Vulgaris
7%
Cytotoxic Agent
7%
Antimalarial
7%
Oral
7%
Side Effect
7%
Clinical Symptom
7%
Immunology and Microbiology
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
100%
Lupus Vulgaris
28%
Immune Complex
21%
B Cell
14%
Immunosuppressive Drug
14%
Antinuclear Antibody
14%
Prevalence
14%
Immunocompetent Cell
14%
Screening Test
14%
Nucleosome
14%
Immune Complex Deposition
14%
Drug-Induced Lupus Erythematosus
14%
Autoimmunity
7%
Autoantibodies
7%
Tacrolimus
7%
C4A
7%
Undifferentiated Connective Tissue Disease
7%
Antimalarial Agent
7%
Monoclonal Antibody
7%
Interleukin 6
7%
Autoimmune Disease
7%
Maturation
7%
Mediator
7%
Face
7%
Ciclosporin
7%
Anti-dsDNA Antibodies
7%
Experimental Model
7%
Prednisone
7%
Scar Formation
7%
CD40 Ligand
7%
CD20
7%
Neck
7%
Maternal Antibody
7%
Life Expectancy
7%
Drug Efficacy
7%
Organ Systems
7%
Drug Targeting
7%
Abatacept
7%
Scalp
7%
Ro Antibody
7%
T Cell
7%
Nephritis
7%
Atherosclerosis
7%
Programmed Cell Death
7%
Infection
7%
Susceptibility
7%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
100%
Inflammation
21%
Prevalence
14%
Antimalarial Agent
14%
Skin Defect
14%
Immunosuppressive Agent
14%
Lupus Like Syndrome
14%
Antinuclear Antibody
14%
Discoid Lupus Erythematosus
14%
Lupus Vulgaris
14%
Diseases
14%
Hydralazine
7%
Observational Study
7%
Ultraviolet Radiation
7%
Drug Delivery System
7%
Cytotoxic Agent
7%
Infection
7%
Atherosclerosis
7%
Non-Steroidal Anti-Inflammatory Drug
7%
Ciclosporin
7%
Lupus Erythematosus Nephritis
7%
Thromboembolism
7%
Heart Injury
7%
Life Expectancy
7%
Cell Receptor
7%
Scar Formation
7%
Skin Manifestation
7%
Disease Course
7%
CD40 Ligand
7%
Ribosome Protein
7%
Alopecia
7%
Maternal Antibody
7%
Skin Lupus Erythematosus
7%
Hypocomplementemia
7%
Ro Antibody
7%
Combination Therapy
7%
Pathophysiology
7%
Autoantibodies
7%
Interleukin 6
7%
Autoimmune Disease
7%
Connective Tissue Disease
7%
Monoclonal Antibody
7%
Tacrolimus
7%
Prednisone
7%
Abatacept
7%
Atrioventricular Block
7%
Myocardial Disease
7%
Self-antigens
7%
Side Effect
7%